Form 4: Agios Pharmaceuticals CMO Exercises Options and Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.
Summary
- Chief Medical Officer Sarah Gheuens exercised options to acquire 11,914 shares of Agios Pharmaceuticals common stock at an exercise price of $25.01 per share on July 9, 2025.
- Concurrently, Gheuens sold a total of 11,914 shares of common stock through two separate transactions on July 9, 2025, under a Rule 10b5-1 trading plan.
- The first sale involved 11,067 shares at a weighted average price of $37.93, with prices ranging from $37.52 to $38.49.
- The second sale involved 847 shares at a weighted average price of $38.76, with prices ranging from $38.55 to $38.87.
- Following these transactions, Gheuens beneficially owns 61,271 shares of common stock and 32,086 unexercised stock options.
- The exercised options were part of an original grant of 44,000 shares on March 1, 2023, vesting 25% on March 1, 2024, and the remainder in 36 equal monthly installments, with an expiration date of March 1, 2033.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to the insider sale of shares, even though it was pre-planned under a 10b5-1 plan. While the exercise of options is a positive for the executive, the subsequent sale reduces their direct equity exposure.
Positives
- The exercise of stock options indicates the insider is realizing value from their compensation.
- Transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned sales and not necessarily a reaction to new, non-public information.
Negatives
- The sale of shares by a Chief Medical Officer could be interpreted as a reduction in direct exposure to the company's stock by a key executive.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may interpret the sale of shares by a key executive as a signal regarding the company's future prospects or the executive's confidence, potentially influencing investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/01/2023 | Original grant date for 44,000 stock options to Sarah Gheuens. |
| 03/01/2024 | Vesting date for 25% of the stock options granted on March 1, 2023. |
| 07/09/2025 | Date of stock option exercise and subsequent sale of common stock by Sarah Gheuens. |
| 07/11/2025 | Signature date of the Form 4 filing by William Cook, attorney-in-fact for Sarah Gheuens. |
| 03/01/2033 | Expiration date of the stock options. |
Keywords
Agios Pharmaceuticals, AGIO, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1, Executive Compensation, Share Sale, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.